Thomas M. Maddox i wsp. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. J Am Coll Cardio. 2020 online
Since the 2017 ECDP, new therapies for HFrEF have emerged that expand the armamentarium for the treatment of patients with HFrEF. In particular, the emergence of angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and percutaneous therapy for mitral regurgitation (MR) represent significant advances in the treatment of HFrEF.
This update can serve as interim guidance to clinicians while we await the comprehensive and definitive heart failure (HF) guideline update under development by the ACC. The treatment of HFrEF can feel overwhelming, and many opportunities to improve patient outcomes are being missed; hopefully, this ECDP will streamline care to realize the best possible patient outcomes in HF.
11 stycznia 2021